Скачать или смотреть JAKARTA-2 Reanalysis Demonstrates Activity With Fedratinib in MF After Ruxolitinib Failure

Ruben Mesa, MD, hematologist at the Mays Cancer Center, discusses the results from a reanalysis of the phase II JAKARTA-2 study in patients with myelofibrosis (MF) who received a previous treatment of ruxolitinib (Jakafi) and failed treatment.

The JAKARTA-2 trial was conducted several years ago, looking at JAK2 inhibitor fedratinib as treatment of patients with MF after ruxolitinib failure. After ruxolitinib was approved by the FDA, however, investigators found that the criteria for ruxolitinib intolerance or resistance needed to be updated. The criteria did not fully capture the activity of fedratinib.

With 8 years of experience in this patient population, investigators reevaluated the criteria to include minimums of 3 months on ruxolitinib therapy, amount of spleen growth, symptoms, cytopenias, and other criteria. In this reanalysis, Mesa says just under 70 patients were evaluated for efficacy with at least 6 months of fedratinib therapy.

Overall, there was a 30% response rate and reduction in the splenomegaly, as well as improvement in symptoms with the use of fedratinib in this patient population. Mesa adds that these findings are encouraging for further development of this agent in the future.

For more resources and information regarding anticancer targeted therapies in MPNs: http://targetedonc.com/resource-cente...